Не говорите ерунды по поводу стоимости Калетра.
А спросите у своего лечащего врача причину замены Калетра на Телзир/Ритонавир.
Телзир не такой уж и новый препарат зарегистрирован в 2006 году.
По поводу предупреждений:
SUMMARY: On December 3, the U.S. Food and Drug Administration (FDA) and manufacturer GlaxoSmithKline (GSK) issued a Dear Healthcare Provider letter alerting clinicians about a potential association between use of the protease inhibitor fosamprenavir (Lexiva) and dyslipidemia (abnormal blood fat levels) and myocardial infarction (heart attack). The warning is based on data from a French study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2009) this past February, showing that fosamprenavir increased the risk of myocardial infarction by 52%. GSK has modified the Warnings and Precautions section of the fosamprenavir prescribing information, and recommends that triglyceride and cholesterol testing should be performed prior to starting fosamprenavir and at periodic intervals during therapy.
3 фев. 2012 г. в 13:31
Россия, Ульяновск
3 фев. 2012 г. в 12:56